AbbVie Biotechnology Ltd.

Bermuda

Back to Profile

Receive daily alerts for new
USPTO trademarks filed by this owner
1-100 of 230 for AbbVie Biotechnology Ltd. Sort by
Query
Aggregations
IP Type
        Patent 146
        Trademark 84
Jurisdiction
        United States 142
        Canada 51
        Europe 27
        World 10
Date
New (last 4 weeks) 8
2021 April 8
2021 March 3
2021 (YTD) 11
2020 10
See more
IPC Class
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum 96
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons 78
A61K 39/00 - Medicinal preparations containing antigens or antibodies 47
A61K 9/00 - Medicinal preparations characterised by special physical form 33
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin 31
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 43
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 39
16 - Paper, cardboard and goods made from these materials 11
35 - Advertising and business services 10
41 - Education, entertainment, sporting and cultural services 10
See more
Status
Pending 36
Registered / In Force 194
  1     2     3        Next Page

1.

PROTEIN FORMULATIONS AND METHODS OF MAKING SAME

      
Application Number 17137201
Status Pending
Filing Date 2020-12-29
First Publication Date 2021-04-29
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Fraunhofer, Wolfgang
  • Bartl, Annika
  • Krause, Hans-Juergen
  • Tschoepe, Markus
  • Kaleta, Katharina

Abstract

The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • A61K 38/21 - Interferons
  • A61K 38/46 - Hydrolases (3)
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
  • C07K 1/34 - Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
  • A61K 38/38 - Albumins
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

2.

ELUVOGE

      
Application Number 018458293
Status Pending
Filing Date 2021-04-22
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain.

3.

FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS

      
Application Number 17126500
Status Pending
Filing Date 2020-12-18
First Publication Date 2021-04-22
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 47/02 - Inorganic compounds

4.

PROTEIN FORMULATIONS AND METHODS OF MAKING SAME

      
Application Number 17137246
Status Pending
Filing Date 2020-12-29
First Publication Date 2021-04-22
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Fraunhofer, Wolfgang
  • Bartl, Annika
  • Krause, Hans-Juergen
  • Tschoepe, Markus
  • Kaleta, Katharina

Abstract

The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • A61K 38/21 - Interferons
  • A61K 38/46 - Hydrolases (3)
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
  • C07K 1/34 - Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
  • A61K 38/38 - Albumins
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

5.

ELUVOGE

      
Serial Number 90660827
Status Pending
Filing Date 2021-04-21
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain

6.

ELUVOGE

      
Application Number 210169200
Status Pending
Filing Date 2021-04-21
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain

7.

KNOWLEDGE COUNTS

      
Serial Number 90650521
Status Pending
Filing Date 2021-04-16
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders pamphlets, brochures, newsletters and books in the field of healthcare providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

8.

A JOURNEY TO POSSIBILITIES

      
Serial Number 90635300
Status Pending
Filing Date 2021-04-09
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders Pamphlets, brochures, newsletters and books in the field of healthcare Providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

9.

READICLICK

      
Application Number 018441388
Status Pending
Filing Date 2021-03-29
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

Surgical and medical apparatus and instruments, namely, a system for delivery of drugs; medical apparatus and instruments, namely, medical devices for administering pharmaceuticals.

10.

READICLICK

      
Application Number 209549100
Status Pending
Filing Date 2021-03-29
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

(1) Surgical and medical apparatus and instruments, namely, a system for delivery of drugs; medical apparatus and instruments, namely, medical devices for administering pharmaceuticals

11.

READICLICK

      
Serial Number 90568600
Status Pending
Filing Date 2021-03-09
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

surgical and medical apparatus and instruments, namely, a system for delivery of drugs; medical apparatus and instruments, namely, medical devices for administering pharmaceuticals

12.

ITCH OUT OF MIND RASH OUT OF SIGHT

      
Serial Number 90269610
Status Pending
Filing Date 2020-10-21
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Providing medical information regarding medical conditions and treatments to patients and healthcare professionals; medical consultation, namely, providing medical advice to healthcare professionals regarding medical conditions and treatment

13.

GOLSAVI

      
Serial Number 90089894
Status Pending
Filing Date 2020-08-03
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

14.

METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES

      
Application Number 16784621
Status Pending
Filing Date 2020-02-07
First Publication Date 2020-06-11
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Fischkoff, Steven A.
  • Kempeni, Joachim
  • Weiss, Roberta

Abstract

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

IPC Classes  ?

  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

15.

SKYRIZI SKYPEN

      
Application Number 018210866
Status Registered
Filing Date 2020-03-13
Registration Date 2020-07-09
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

Injection devices for pharmaceuticals, namely, medical injection devices for administering drugs.

16.

SKYRIZI SKYJR

      
Application Number 018210870
Status Registered
Filing Date 2020-03-13
Registration Date 2020-07-09
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

Injection devices for pharmaceuticals, namely, medical injection devices for administering drugs.

17.

SKYRIZI SKYDOSE

      
Application Number 018210872
Status Registered
Filing Date 2020-03-13
Registration Date 2020-07-09
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

Injection devices for pharmaceuticals, namely, medical injection devices for administering drugs.

18.

SKYRIZI SKYPEN

      
Application Number 201742900
Status Pending
Filing Date 2020-03-12
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

(1) Injection devices for pharmaceuticals, namely, medical injection devices for administering drugs

19.

SKYRIZI SKYDOSE

      
Application Number 201743100
Status Pending
Filing Date 2020-03-12
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

(1) Injection devices for pharmaceuticals, namely, medical injection devices for administering drugs

20.

SKYRIZI SKYJR

      
Application Number 201743000
Status Pending
Filing Date 2020-03-12
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

(1) Injection devices for pharmaceuticals, namely, medical injection devices for administering drugs

21.

Miscellaneous Design

      
Serial Number 88764325
Status Pending
Filing Date 2020-01-17
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

22.

PROTEIN FORMULATIONS AND METHODS OF MAKING SAME

      
Application Number 16228478
Status Pending
Filing Date 2018-12-20
First Publication Date 2019-11-28
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Fraunhofer, Wolfgang
  • Bartl, Annika
  • Krause, Hans-Juergen
  • Tschoepe, Markus
  • Kaleta, Katharina

Abstract

The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • A61K 38/38 - Albumins
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K 1/34 - Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
  • A61K 38/46 - Hydrolases (3)
  • A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 38/21 - Interferons
  • A61K 9/08 - Solutions
  • A61K 9/00 - Medicinal preparations characterised by special physical form

23.

PURIFIED ANTIBODY COMPOSITION

      
Application Number 16184374
Status Pending
Filing Date 2018-11-08
First Publication Date 2019-10-03
Owner AbbVie Biotechnology Ltd (Bermuda)
Inventor
  • Wan, Min M.
  • Avgerinos, George
  • Zarbis-Papastoitsis, Gregory

Abstract

The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 1/36 - Extraction; Separation; Purification by a combination of two or more processes of different types
  • C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • C07K 1/18 - Ion-exchange chromatography
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

24.

NUJUPA

      
Serial Number 88637566
Status Pending
Filing Date 2019-10-01
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

25.

IBDISCOVER UC CD

      
Serial Number 88613961
Status Registered
Filing Date 2019-09-12
Registration Date 2020-06-16
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

providing a website featuring medical information; providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals

26.

MANAGING HEALTHCARE SERVICES

      
Application Number 16410520
Status Pending
Filing Date 2019-05-13
First Publication Date 2019-08-29
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Stueckemann, Peter Carl
  • Dubey, Pankaj
  • Lanier, Richard
  • Venkataramanan, Prakash
  • Jindal, Vaibhav
  • Sword, Shannon Marie

Abstract

A system for facilitating a medical order/prescription of a prescription product is provided. The system includes a memory device having stored therein a plurality of predefined forms, a receiver configured to receive (i) prescription product information from a healthcare provider (HCP) computing device, (ii) patient intake information, and (iii) a benefits summary in response to a benefits verification request, and a processor configured to generate the benefits verification request for the patient based on the patient intake information, select one of the predefined forms, populate the selected predefined form, generate a patient history based on at least one of the benefits summary and the populated form, and cause the patient history to be displayed on the HCP computing device, the displayed patient history including at least one of a date associated with receipt of the benefits summary by the HCP computing device and an expiration date of the populated form.

IPC Classes  ?

  • G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
  • G06Q 40/08 - Insurance, e.g. risk analysis or pensions
  • G06Q 30/06 - Buying, selling or leasing transactions
  • G06Q 50/22 - Social work

27.

RHEUM FOR MORE

      
Serial Number 88472028
Status Registered
Filing Date 2019-06-13
Registration Date 2020-07-28
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ?
  • 41 - Education, entertainment, sporting and cultural services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Providing a website featuring nondownloadable publications in the nature of brochures, articles and newsletters in the field of health; educational services, namely, training in the field of immunology, auto-immune diseases, rheumatology and treatments thereof providing health information; providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

28.

SKYRIZI COMPLETE

      
Serial Number 88385582
Status Registered
Filing Date 2019-04-15
Registration Date 2021-03-23
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 41 - Education, entertainment, sporting and cultural services

Goods & Services

Providing a website featuring nondownloadable publications in the nature of brochures, articles and newsletters in the field of health; Educational services, namely, training in the field of immunology, auto-immune diseases, dermatology, rheumatology, gastroenterology and treatments thereof

29.

HUMIRA COMPLETE

      
Serial Number 88329274
Status Registered
Filing Date 2019-03-07
Registration Date 2020-03-24
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ?
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Providing a website featuring nondownloadable publications in the nature of brochures, articles and newsletters in the field of health; Educational services, namely, training in the field of immunology, auto-immune diseases, dermatology, rheumatology, gastroenterology and treatments thereof Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of immunology, auto-immune diseases, dermatology, rheumatology, gastroenterology and treatments thereof via the internet, digital media and data banks; Providing scientific research information concerning clinical study results and clinical study data by means of interactive web sites; Providing scientific information in the field of epidemiology, disease background, real world evidence, pharmaceuticals and clinical trials; providing scientific information in the field of immunology, auto-immune diseases, dermatology, rheumatology, gastroenterology and treatments thereof via the internet, digital media and data banks; provision of scientific information concerning epidemiological study results, real world evidence, clinical study results and clinical study data by means of interactive web sites; providing an interactive web site featuring scientific information on clinical studies and clinical study results Providing health information

30.

PED-MUS

      
Application Number 194567000
Status Pending
Filing Date 2019-02-11
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Providing medical information to rheumatologists in the form of reports in the field of conducting ultrasounds on pediatric patients to improve diagnosis and disease management

31.

Ped-MUS

      
Application Number 018021274
Status Registered
Filing Date 2019-02-11
Registration Date 2019-06-25
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Providing medical information to rheumatologists in the form of reports in the field of conducting ultrasounds on pediatric patients to improve diagnosis and disease management.

32.

PED-MUS

      
Serial Number 88258289
Status Registered
Filing Date 2019-01-11
Registration Date 2020-03-24
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

providing medical information to rheumatologists in the form of reports in the field of conducting ultrasounds on pediatric patients to improve diagnosis and disease management

33.

NOTHING IS EVERYTHING

      
Application Number 017976535
Status Registered
Filing Date 2018-10-30
Registration Date 2019-03-13
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment.

34.

INFINITY DEVICE (in colour)

      
Application Number 192774500
Status Pending
Filing Date 2018-10-29
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations

35.

Miscellaneous Design

      
Application Number 017975963
Status Registered
Filing Date 2018-10-29
Registration Date 2019-03-01
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

36.

Miscellaneous Design

      
Application Number 017975996
Status Registered
Filing Date 2018-10-29
Registration Date 2019-03-01
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

37.

NOTHING IS EVERYTHING

      
Application Number 192774700
Status Pending
Filing Date 2018-10-29
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ?
  • 35 - Advertising and business services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

38.

C

      
Application Number 192751800
Status Pending
Filing Date 2018-10-26
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations

39.

Miscellaneous Design

      
Serial Number 88171017
Status Registered
Filing Date 2018-10-26
Registration Date 2019-11-26
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

40.

Miscellaneous Design

      
Serial Number 88171100
Status Registered
Filing Date 2018-10-26
Registration Date 2019-07-30
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

41.

NOTHING IS EVERYTHING

      
Serial Number 88171178
Status Registered
Filing Date 2018-10-26
Registration Date 2020-05-26
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ?
  • 35 - Advertising and business services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

providing medical information, namely, consumer product information regarding medical products to patients and healthcare professionals providing medical information, namely, information regarding medical conditions, treatments to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

42.

REMOVAL OF NEEDLE SHIELD FROM SYRINGES AND AUTOMATIC INJECTION DEVICES

      
Application Number 16022399
Status Pending
Filing Date 2018-06-28
First Publication Date 2018-10-25
Owner
  • AbbVie Biotechnology Ltd (Bermuda)
  • Elcam Medical Agricultural Cooperative Association Ltd. (Israel)
Inventor
  • Julian, Joseph F.
  • Li, Chuan
  • Anderson, Philip D.
  • Laurusonis, Linas P.
  • Raday, Lior
  • Carmel, Ehud
  • Marli, Lior
  • Daily, David
  • Keenan, Guy

Abstract

Exemplary embodiments provide a needle shield remover that reliably engages with a distal cap of an automatic injection device and with one or more needle shields coupled to a syringe of the device. When a user removes the distal cap, the needle shield remover reliably removes the needle shields (e.g., a soft needle shield and a rigid needle shield) from the syringe, thereby exposing the injection needle for performing an injection. In an exemplary assembly method, a needle shield remover is engaged to a needle shield coupled to a syringe, prior to insertion of the syringe and needle shield remover assembly into a housing of the device. This exemplary assembly method allows visual inspection, outside the housing of the device, to ensure that the needle shield remover is correctly and reliably engaged to the needle shield before the syringe and needle shield remover assembly is inserted into the housing.

IPC Classes  ?

  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically

43.

BODY OF PROOF

      
Serial Number 88151635
Status Registered
Filing Date 2018-10-11
Registration Date 2019-12-31
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ?
  • 35 - Advertising and business services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

providing consumer product information regarding medical products to patients and healthcare professionals Providing medical information, namely, information regarding medical conditions, treatments to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

44.

ELUVOGUE

      
Application Number 192299100
Status Pending
Filing Date 2018-10-01
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations for the treatment of viral diseases, namely herpes, hepatitis, acquired immune deficiency syndrome (AIDS); pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, bulimia nervosa, anorexia, obesity, hypothyroidism, hypoglycemia, gout, osteoarthritis, muscular dystrophy and anemia; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue disease, bone diseases, spinal diseases, back pain, fractures, sprains and cartilage injuries; pharmaceutical preparations for the treatment of cardiovascular and cardiopulmonary diseases and disorders; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, incontinence, inflammatory pelvic diseases and sexual dysfunction; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of ophthalmic, respiratory and gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of neurological diseases and disorders, namely, Parkinson's, Alzheimer's, Huntington's disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders and schizophrenia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes; pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain.

45.

AUTOMATIC INJECTION DEVICES HAVING OVERMOLDED GRIPPING SURFACES

      
Application Number 15880980
Status Pending
Filing Date 2018-01-26
First Publication Date 2018-05-31
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Julian, Joseph F.
  • Li, Chuan
  • Eiger, Aaron B.
  • Kurth, Mark
  • Katz, Sabrina
  • Callif, Adam
  • Stango, James C.

Abstract

Exemplary embodiments provide automatic injection devices, housing components for automatic injection devices and methods for fabricating the same. An exemplary housing of an automatic injection device may be overmolded with one or more gripping surfaces to facilitate gripping and manipulation of the automatic injection device by a user when performing an injection. In an exemplary embodiment, an overmolded left gripping surface may extend along a left side of the housing and an overmolded right gripping surface may extend along a right side of the housing opposite to the left side.

IPC Classes  ?

  • A61M 5/31 - Syringes - Details
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
  • A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing
  • A61B 5/15 - Devices for taking samples of blood
  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles

46.

ELUVOGUE

      
Serial Number 87874399
Status Pending
Filing Date 2018-04-12
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

47.

ELUVOGUE

      
Application Number 017887250
Status Registered
Filing Date 2018-04-12
Registration Date 2018-07-29
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders.

48.

DEFY EXPECTATIONS

      
Serial Number 87835262
Status Registered
Filing Date 2018-03-15
Registration Date 2020-04-07
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

49.

DEFY EXPECTATIONS

      
Application Number 188732400
Status Registered
Filing Date 2018-03-09
Registration Date 2020-01-08
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals concerning viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical consultation, namely, providing advice to healthcare professionals regarding viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and treatment thereof

50.

Purified antibody composition

      
Application Number 15718621
Grant Number 09913902
Status In Force
Filing Date 2017-09-28
First Publication Date 2018-02-08
Grant Date 2018-03-13
Owner ABBVIE BIOTECHNOLOGY LTD. (Bermuda)
Inventor
  • Wan, Min M.
  • Avgerinos, George
  • Zarbis-Papastoitsis, Gregory

Abstract

The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
  • C07K 1/36 - Extraction; Separation; Purification by a combination of two or more processes of different types
  • C07K 1/18 - Ion-exchange chromatography
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

51.

IBD Let's change lives

      
Application Number 017719253
Status Registered
Filing Date 2018-01-22
Registration Date 2018-05-22
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Provision of medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals and promoting awareness of inflammatory bowel disease among consumers, health care professionals and government agencies in Class 44.

52.

A JOURNEY TO POSSIBILITIES

      
Serial Number 87653653
Status Pending
Filing Date 2017-10-20
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders Pamphlets, brochures, newsletters and books in the field of healthcare Providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; Medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

53.

KNOWLEDGE COUNTS

      
Serial Number 87653663
Status Pending
Filing Date 2017-10-20
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders Pamphlets, brochures, newsletters and books in the field of healthcare Providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; Medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

54.

KAZVI

      
Application Number 017259995
Status Registered
Filing Date 2017-09-28
Registration Date 2018-01-12
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

55.

HINZIB

      
Application Number 017260035
Status Registered
Filing Date 2017-09-28
Registration Date 2018-01-12
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations.

56.

PSORIASIS SPEAKS

      
Serial Number 87607896
Status Registered
Filing Date 2017-09-14
Registration Date 2018-05-08
Owner AbbVie Biotechnology Ltd (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Providing medical information to patients and healthcare professionals, namely, information regarding medical conditions and treatments; Medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

57.

GOLSAVI

      
Application Number 184835500
Status Registered
Filing Date 2017-07-19
Registration Date 2020-05-07
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations and substances for the treatment of viral diseases, namely herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations and substances for the treatment of metabolic diseases and disorders, namely diabetes, bulimia nervosa, anorexia, obesity, hypothyroidism, hypoglycemia, gout, osteoarthritis, muscular dystrophy and anemia; pharmaceutical preparations and substances for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations and substances for the treatment of the musculoskeletal system, namely, connective tissue disease, bone diseases, spinal diseases, back pain, fractures, sprains and cartilage injuries; pharmaceutical preparations and substances for the treatment of cardiovascular and cardiopulmonary diseases and disorders; pharmaceutical preparations and substances for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, incontinence, inflammatory pelvic diseases and sexual dysfunction; pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of ophthalmic, respiratory and gastrointestinal diseases and disorders; pharmaceutical preparations and substances for the treatment of neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations and substances for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders and schizophrenia; pharmaceutical preparations and substances for the treatment of immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes

58.

SKYRIZI

      
Application Number 184835600
Status Registered
Filing Date 2017-07-19
Registration Date 2019-06-17
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations and substances for the treatment of viral diseases, namely herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations and substances for the treatment of metabolic diseases and disorders, namely diabetes, bulimia nervosa, anorexia, obesity, hypothyroidism, hypoglycemia, gout, osteoarthritis, muscular dystrophy and anemia; pharmaceutical preparations and substances for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations and substances for the treatment of the musculoskeletal system, namely, connective tissue disease, bone diseases, spinal diseases, back pain, fractures, sprains and cartilage injuries; pharmaceutical preparations and substances for the treatment of cardiovascular and cardiopulmonary diseases and disorders; pharmaceutical preparations and substances for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, incontinence, inflammatory pelvic diseases and sexual dysfunction; pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of ophthalmic, respiratory and gastrointestinal diseases and disorders; pharmaceutical preparations and substances for the treatment of neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations and substances for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders and schizophrenia; pharmaceutical preparations and substances for the treatment of immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes

59.

GOLSAVI

      
Application Number 016998874
Status Registered
Filing Date 2017-07-19
Registration Date 2017-11-03
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders.

60.

RINVOQ

      
Application Number 016998891
Status Registered
Filing Date 2017-07-19
Registration Date 2017-11-06
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders.

61.

SKYRIZI

      
Application Number 016999047
Status Registered
Filing Date 2017-07-19
Registration Date 2020-02-27
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; all of the aforementioned provided by prescription.

62.

RINVOQ

      
Application Number 184835400
Status Registered
Filing Date 2017-07-19
Registration Date 2019-06-17
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations and substances for the treatment of viral diseases, namely herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations and substances for the treatment of metabolic diseases and disorders, namely diabetes, bulimia nervosa, anorexia, obesity, hypothyroidism, hypoglycemia, gout, osteoarthritis, muscular dystrophy and anemia; pharmaceutical preparations and substances for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations and substances for the treatment of the musculoskeletal system, namely, connective tissue disease, bone diseases, spinal diseases, back pain, fractures, sprains and cartilage injuries; pharmaceutical preparations and substances for the treatment of cardiovascular and cardiopulmonary diseases and disorders; pharmaceutical preparations and substances for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, incontinence, inflammatory pelvic diseases and sexual dysfunction; pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of ophthalmic, respiratory and gastrointestinal diseases and disorders; pharmaceutical preparations and substances for the treatment of neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations and substances for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders and schizophrenia; pharmaceutical preparations and substances for the treatment of immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes

63.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 15418469
Grant Number 09738714
Status In Force
Filing Date 2017-01-27
First Publication Date 2017-06-08
Grant Date 2017-08-22
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • C07K 14/525 - Tumour necrosis factor (TNF)

64.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 15418460
Grant Number 09750808
Status In Force
Filing Date 2017-01-27
First Publication Date 2017-06-01
Grant Date 2017-09-05
Owner ABBVIE BIOTECHNOLOGY LTD. (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • C07K 14/525 - Tumour necrosis factor (TNF)

65.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 15418465
Grant Number 09732152
Status In Force
Filing Date 2017-01-27
First Publication Date 2017-05-25
Grant Date 2017-08-15
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • C07K 14/525 - Tumour necrosis factor (TNF)

66.

HS Learning Rx

      
Application Number 182904900
Status Registered
Filing Date 2017-03-23
Registration Date 2021-01-13
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ?
  • 35 - Advertising and business services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Research services in the field of auto-immune disorders; hosting an interactive website for patients that provides healthcare professional support and healthcare information (2) Medical services namely medical counseling and diagnostic services in the field of auto-immune disorders; health and well-being services, namely personal and emotional support services for families of patients with health disorders and providing medical consultation regarding same; health assessment services namely provision of information to healthcare professionals and patients on self-health assessment; a patient assistance and support program namely, providing support in the delivery and administration of medication; the operation of a patient telephone help line to provide healthcare professional support, medical advice; health management services namely holistic health services to support patients' physical, mental and emotional general health and well-being, patient support programs to assist with patients' general health and well-being, health coaching services to support patients' general health and well-being and health mentoring services to support patients' general health and well-being; nursing and personal caregiver services; preventative health care services and programs, namely nutrition, lifestyle, and medication management counseling; chronic disease management services and programs, namely nutrition, lifestyle, and medication management counseling; hospital substitute services and programs, namely home health care services; occupational health and safety services, namely therapeutic and rehabilitation services; medical counseling services in the field of auto-immune disorders; pharmacy advice and pharmacy dispensary services; drug administration services, alternative medical services and complementary medical services, namely homeopathy services; consultancy and advisory services in relation to auto-immune disorders; providing information in relation to auto-immune disorders

67.

HUMIRA &GO

      
Serial Number 87379037
Status Registered
Filing Date 2017-03-21
Registration Date 2018-11-20
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

68.

WHAT'S YOUR GO

      
Serial Number 87379045
Status Registered
Filing Date 2017-03-21
Registration Date 2020-04-07
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment

69.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 15095393
Grant Number 09950066
Status In Force
Filing Date 2016-04-11
First Publication Date 2017-03-02
Grant Date 2018-04-24
Owner AbbVie Biotechnology Ltd (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 47/02 - Inorganic compounds
  • C07K 14/525 - Tumour necrosis factor (TNF)
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

70.

MY IBD GAME PLAN

      
Serial Number 87353991
Status Registered
Filing Date 2017-03-01
Registration Date 2018-11-20
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

providing a website featuring medical information; providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals

71.

LONIC

      
Application Number 182325700
Status Registered
Filing Date 2017-02-16
Registration Date 2020-02-12
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

(1) Pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), metabolic diseases, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, endocrine diseases, namely, growth and thyroid disorders, musculoskeletal system diseases and disorders, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, cardiovascular, cardiopulmonary, genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases, reproductive diseases, namely, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, seizure disorders, gastrointestinal, hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations, pharmaceutical preparations for use in dermatology, namely, dermatitis, psoriasis, skin pigmentation diseases, sexually transmitted diseases, psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis, sleep, central nervous system and immune system related diseases and disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, autoimmune diseases, and immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, blood disorders, pain, inflammation diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, sepsis, alopecia, obesity and cognitive disorders (1) Manufacturing services in the field of low ionic formulation of proteins; chemical treatment processing of pharmaceutical agents in the field of low ionic formulation of proteins (2) Medical research and product development in the field of low ionic formulation of proteins

72.

RINVOQ

      
Serial Number 87320921
Status Registered
Filing Date 2017-02-01
Registration Date 2019-11-12
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

73.

SKYRIZI

      
Serial Number 87320935
Status Registered
Filing Date 2017-02-01
Registration Date 2019-09-10
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

74.

RHEUMOTION

      
Application Number 016160591
Status Registered
Filing Date 2016-12-13
Registration Date 2017-05-04
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ?
  • 41 - Education, entertainment, sporting and cultural services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Education; providing of training; sporting activities; fitness training; health training. Medical services; health counselling; health care.

75.

Timer

      
Application Number 29525618
Grant Number D0772733
Status In Force
Filing Date 2015-04-30
First Publication Date 2016-11-29
Grant Date 2016-11-29
Owner ABBVIE BIOTECHNOLOGY LTD. (Bermuda)
Inventor
  • Stueckemann, Peter C.
  • Bock-Aronson, Max
  • Harris, Christopher Alan

76.

Methods of administering anti-TNFα antibodies

      
Application Number 15179803
Grant Number 09546212
Status In Force
Filing Date 2016-06-10
First Publication Date 2016-09-29
Grant Date 2017-01-17
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Fischkoff, Steven A.
  • Kempeni, Joachim
  • Weiss, Roberta

Abstract

−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

77.

Use of TNFα inhibitor

      
Application Number 15173191
Grant Number 09512216
Status In Force
Filing Date 2016-06-03
First Publication Date 2016-09-22
Grant Date 2016-12-06
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Hoffman, Rebecca S.
  • Weinberg, Mark
  • Taylor, Lori K.
  • Chartash, Elliot K.
  • Yan, Philip
  • Granneman, George R.

Abstract

The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

IPC Classes  ?

  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 9/00 - Medicinal preparations characterised by special physical form

78.

Removal of needle shield from syringes and automatic injection devices

      
Application Number 15094364
Grant Number 10022503
Status In Force
Filing Date 2016-04-08
First Publication Date 2016-08-04
Grant Date 2018-07-17
Owner
  • AbbVie Biotechnology Ltd (Bermuda)
  • Elcam Medical Agricultural Cooperative Association Ltd (Israel)
Inventor
  • Julian, Joseph F.
  • Li, Chuan
  • Anderson, Philip D.
  • Laurusonis, Linas P.
  • Raday, Lior
  • Carmel, Ehud
  • Marli, Lior
  • Daily, David
  • Keenan, Guy

Abstract

Exemplary embodiments provide a needle shield remover that reliably engages with a distal cap of an automatic injection device and with one or more needle shields coupled to a syringe of the device. When a user removes the distal cap, the needle shield remover reliably removes the needle shields (e.g., a soft needle shield and a rigid needle shield) from the syringe, thereby exposing the injection needle for performing an injection. In an exemplary assembly method, a needle shield remover is engaged to a needle shield coupled to a syringe, prior to insertion of the syringe and needle shield remover assembly into a housing of the device. This exemplary assembly method allows visual inspection, outside the housing of the device, to ensure that the needle shield remover is correctly and reliably engaged to the needle shield before the syringe and needle shield remover assembly is inserted into the housing.

IPC Classes  ?

  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically

79.

Medication container

      
Application Number 29525610
Grant Number D0761551
Status In Force
Filing Date 2015-04-30
First Publication Date 2016-07-19
Grant Date 2016-07-19
Owner ABBVIE BIOTECHNOLOGY LTD. (Bermuda)
Inventor
  • Stueckemann, Peter C.
  • Bock-Aronson, Max
  • Harris, Christopher Alan

80.

Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease

      
Application Number 14804164
Grant Number 09499615
Status In Force
Filing Date 2015-07-20
First Publication Date 2016-06-30
Grant Date 2016-11-22
Owner ABBVIE BIOTECHNOLOGY LTD. (Bermuda)
Inventor
  • Hoffman, Rebecca S.
  • Chartash, Elliot K.
  • Taylor, Lori K.
  • Granneman, George R.
  • Yan, Philip

Abstract

Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

81.

Automatic injection devices having overmolded gripping surfaces

      
Application Number 15047262
Grant Number 09878102
Status In Force
Filing Date 2016-02-18
First Publication Date 2016-06-09
Grant Date 2018-01-30
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Julian, Joseph F.
  • Li, Chuan
  • Eiger, Aaron B.
  • Kurth, Mark
  • Katz, Sabrina
  • Callif, Adam
  • Stango, James C.

Abstract

Exemplary embodiments provide automatic injection devices, housing components for automatic injection devices and methods for fabricating the same. An exemplary housing of an automatic injection device may be overmolded with one or more gripping surfaces to facilitate gripping and manipulation of the automatic injection device by a user when performing an injection. In an exemplary embodiment, an overmolded left gripping surface may extend along a left side of the housing and an overmolded right gripping surface may extend along a right side of the housing opposite to the left side.

IPC Classes  ?

  • A61M 5/31 - Syringes - Details
  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
  • B23P 17/04 - Metal-working operations, not covered by a single other subclass or another group in this subclass characterised by the nature of the material involved or the kind of product independently of its shape
  • B05D 1/36 - Successively applying liquids or other fluent materials, e.g. without intermediate treatment
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
  • A61B 5/15 - Devices for taking samples of blood
  • A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing

82.

Methods for treating juvenile idiopathic arthritis

      
Application Number 15043108
Grant Number 09669093
Status In Force
Filing Date 2016-02-12
First Publication Date 2016-06-02
Grant Date 2017-06-06
Owner AbbVie Biotechnology Ltd (Bermuda)
Inventor
  • Medich, John R.
  • Paulson, Susan K.
  • Noertersheuser, Peter A.

Abstract

The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

83.

Automatic injection device

      
Application Number 14935085
Grant Number 09486584
Status In Force
Filing Date 2015-11-06
First Publication Date 2016-03-31
Grant Date 2016-11-08
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Julian, Joseph F.
  • Rolfe, Steven
  • Bicknell, Stephen
  • Marshall, Jeremy

Abstract

A method for treating a disorder using an automatic injection device is disclosed. The device includes a syringe movably disposed in a housing and including a barrel portion, a needle and a bung for sealing the barrel portion. The device includes a syringe actuation component for moving the syringe towards a first open end of the housing such that the needle projects from the first end, and for subsequently applying pressure to the bung. The syringe actuation component includes a pressurizer, a rod comprising a compressible portion projecting therefrom, and a flange between a second end of the rod and the compressible portion. The device also includes a biasing mechanism for biasing the syringe actuation component towards the first open end of the housing, the biasing mechanism disposed about the second end of the rod between the flange and a second end of the housing.

IPC Classes  ?

  • G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
  • A61M 5/31 - Syringes - Details
  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
  • A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
  • A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing

84.

Wearable automatic injection device for controlled delivery of therapeutic agents

      
Application Number 14872949
Grant Number 09821117
Status In Force
Filing Date 2015-10-01
First Publication Date 2016-03-24
Grant Date 2017-11-21
Owner AbbVie Biotechnology Ltd (Bermuda)
Inventor
  • Anderson, Philip D.
  • Julian, Joseph F.
  • Laurusonis, Linas P.
  • Parmer, Timothy
  • Yoch, Travis
  • Jang, Samuel M.
  • Corrigan, Sean
  • Matusaitis, Tomas
  • Fienup, William
  • Strahm, Chris

Abstract

Exemplary embodiments provide wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates, for example, in a single bolus. Exemplary embodiments provide methods for assembling wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates. Exemplary embodiments provide methods for using wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates.

IPC Classes  ?

  • A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
  • A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
  • A61M 5/142 - Pressure infusion, e.g. using pumps
  • A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
  • A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
  • A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
  • A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
  • A61M 5/158 - Needles
  • A61M 5/31 - Syringes - Details
  • A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing
  • A61M 5/34 - Constructions for connecting the needle

85.

Methods for treating juvenile idiopathic arthritis

      
Application Number 14679476
Grant Number 09284370
Status In Force
Filing Date 2015-04-06
First Publication Date 2016-03-03
Grant Date 2016-03-15
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Medich, John R.
  • Paulson, Susan K.
  • Noertersheuser, Peter A.

Abstract

The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)

86.

HSAssist

      
Application Number 177037400
Status Registered
Filing Date 2016-03-02
Registration Date 2019-02-25
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ?
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
  • 45 - Legal and security services; personal services for individuals.

Goods & Services

(1) Medical services, namely medical counseling, diagnostic and research services in the field of auto-immune disorders; health and well-being services, namely providing support, medical advice, and educational information and training to healthcare professionals and patients in connection with auto-immune disorders; health assessment services, namely provision of information to healthcare professionals and patients on self-health assessment; a patient assistance and support program namely, providing support in the delivery and administration of medication; the operation of a patient telephone help line to provide healthcare professional support, medical advice, educational information and training in the field of healthcare to patients on the delivery and administration of medication; the operation of an interactive website for patients that provides healthcare professional support, information and training on delivery and administration of medication; health management services, namely holistic health services to support patients' physical, mental and emotional general health and well-being, patient support programs, health coaching services to support patients' general health and well-being and health mentoring services to support patients' general health and well-being; nursing and personal caregiver services; preventative health care services and programs, namely nutrition, lifestyle, and medication management counseling; chronic disease management services and programs, namely nutrition, lifestyle, and medication management counseling; hospital substitute services and programs, namely home health care services; occupational health and safety services and programs, namely therapeutic and rehabilitation services; pharmacy advice and pharmacy dispensary services; drug administration services, alternative medical services and complementary medical services, namely homeopathy services; consultancy and advisory services in relation to auto-immune disorders; providing information in relation to auto-immune disorders

87.

HS ASSIST

      
Application Number 177037500
Status Registered
Filing Date 2016-03-02
Registration Date 2019-02-25
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ?
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
  • 45 - Legal and security services; personal services for individuals.

Goods & Services

(1) Medical services, namely medical counseling, diagnostic and research services in the field of auto-immune disorders; health and well-being services, namely providing support, medical advice, and educational information and training to healthcare professionals and patients in connection with auto-immune disorders; health assessment services, namely provision of information to healthcare professionals and patients on self-health assessment; a patient assistance and support program namely, providing support in the delivery and administration of medication; the operation of a patient telephone help line to provide healthcare professional support, medical advice, educational information and training in the field of healthcare to patients on the delivery and administration of medication; the operation of an interactive website for patients that provides healthcare professional support, information and training on delivery and administration of medication; health management services, namely holistic health services to support patients' physical, mental and emotional general health and well-being, patient support programs, health coaching services to support patients' general health and well-being and health mentoring services to support patients' general health and well-being; nursing and personal caregiver services; preventative health care services and programs, namely nutrition, lifestyle, and medication management counseling; chronic disease management services and programs, namely nutrition, lifestyle, and medication management counseling; hospital substitute services and programs, namely home health care services; occupational health and safety services and programs, namely therapeutic and rehabilitation services; pharmacy advice and pharmacy dispensary services; drug administration services, alternative medical services and complementary medical services, namely homeopathy services; consultancy and advisory services in relation to auto-immune disorders; providing information in relation to auto-immune disorders

88.

Formulation of human antibodies for treating TNF-α associated disorders

      
Application Number 14884279
Grant Number 09302011
Status In Force
Filing Date 2015-10-15
First Publication Date 2016-02-04
Grant Date 2016-04-05
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/02 - Inorganic compounds
  • C07K 14/525 - Tumour necrosis factor (TNF)
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

89.

Purified antibody composition

      
Application Number 14841439
Grant Number 09328165
Status In Force
Filing Date 2015-08-31
First Publication Date 2015-12-17
Grant Date 2016-05-03
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Wan, Min M.
  • Avgerinos, George
  • Zarbis-Papastoitsis, Gregory

Abstract

The invention provides a method for producing a host cell protein—(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K 1/18 - Ion-exchange chromatography
  • C07K 1/36 - Extraction; Separation; Purification by a combination of two or more processes of different types
  • C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

90.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 14826357
Grant Number 09327032
Status In Force
Filing Date 2015-08-14
First Publication Date 2015-12-03
Grant Date 2016-05-03
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/02 - Inorganic compounds
  • C07K 14/525 - Tumour necrosis factor (TNF)
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

91.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 14826377
Grant Number 09295725
Status In Force
Filing Date 2015-08-14
First Publication Date 2015-12-03
Grant Date 2016-03-29
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/02 - Inorganic compounds
  • C07K 14/525 - Tumour necrosis factor (TNF)
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

92.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 14826393
Grant Number 09289497
Status In Force
Filing Date 2015-08-14
First Publication Date 2015-12-03
Grant Date 2016-03-22
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/02 - Inorganic compounds
  • C07K 14/525 - Tumour necrosis factor (TNF)
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

93.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 14826367
Grant Number 09272041
Status In Force
Filing Date 2015-08-14
First Publication Date 2015-12-03
Grant Date 2016-03-01
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • C07K 14/525 - Tumour necrosis factor (TNF)
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/02 - Inorganic compounds
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

94.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 14826383
Grant Number 09272042
Status In Force
Filing Date 2015-08-14
First Publication Date 2015-12-03
Grant Date 2016-03-01
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • C07K 14/525 - Tumour necrosis factor (TNF)
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/02 - Inorganic compounds
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

95.

Purified antibody composition

      
Application Number 14796779
Grant Number 09273132
Status In Force
Filing Date 2015-07-10
First Publication Date 2015-10-29
Grant Date 2016-03-01
Owner AbbVie Biotechnology Ltd (Bermuda)
Inventor
  • Wan, Min M.
  • Avgerinos, George
  • Zarbis-Papastoitsis, Gregory

Abstract

The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K 1/18 - Ion-exchange chromatography
  • C07K 1/36 - Extraction; Separation; Purification by a combination of two or more processes of different types
  • C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

96.

Formulation of human antibodies for treating TNF-alpha associated disorders

      
Application Number 14799211
Grant Number 09220781
Status In Force
Filing Date 2015-07-14
First Publication Date 2015-10-29
Grant Date 2015-12-29
Owner ABBVIE BIOTECHNOLOGY LTD (Bermuda)
Inventor
  • Krause, Hans-Juergen
  • Baust, Lisa
  • Dickes, Michael

Abstract

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

IPC Classes  ?

  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • C07K 14/525 - Tumour necrosis factor (TNF)
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 9/19 - Particulate form, e.g. powders lyophilised
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/02 - Inorganic compounds
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

97.

PROGRESS

      
Application Number 174043300
Status Registered
Filing Date 2015-08-05
Registration Date 2018-07-20
Owner AbbVie Biotechnology Ltd. (Bermuda)
NICE Classes  ? 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Providing medical information services in the field of health care; providing information concerning medicines; providing medical information for medical, scientific research, and regulatory purposes; informational services in the field of health care; providing medical information in the field of health care via telephone, facsimile, mail, email, private network, printed materials, and the internet.

98.

Use of TNFα inhibitor for treatment of psoriasis

      
Application Number 14681704
Grant Number 09090689
Status In Force
Filing Date 2015-04-08
First Publication Date 2015-07-28
Grant Date 2015-07-28
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Hoffman, Rebecca S.
  • Weinberg, Mark
  • Banerjee, Subhashis
  • Taylor, Lori K.
  • Spiegler, Clive E.
  • Tracey, Daniel E.
  • Chartash, Elliot K.
  • Barchuk, William T.
  • Yan, Philip
  • Murtaza, Anwar
  • Salfeld, Jochen G.
  • Fischkoff, Steven A.
  • Granneman, George R.

Abstract

The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

99.

MANAGING HEALTHCARE SERVICES

      
Application Number US2015011728
Publication Number 2015/109167
Status In Force
Filing Date 2015-01-16
Publication Date 2015-07-23
Owner ABBVIE BIOTECHNOLOGY LTD. (Bermuda)
Inventor
  • Dubey, Pankaj
  • Lanier, Richard
  • Venkataramanan, Prakash
  • Jindal, Vaibhav
  • Sword, Shannon, Marie
  • Wonderling, Corey
  • Kittaneh, Mariam
  • Johnson, Tywana, Lanay
  • Kirsch, Jonathan, Richard

Abstract

A computer system for processing a prescription for a prescription product prescribed by a healthcare provider (HCP) to a patient includes a memory device and a processor. The processor is programmed to receive patient data and insurance data from an HCP computing device, the patient data including a completed prescription form for the prescription product, and the insurance data identifying an insurance provider, wherein the prescription product is an antiviral product, store the patient data and the insurance data, determine a current electronic prior authorization request form, transmit the determined current electronic prior authorization request form to the HCP computing device, and prompt an HCP user to complete the determined current electronic prior authorization request form by enabling the HCP user to automatically populate at least one data field included within the determined current electronic prior authorization request form.

IPC Classes  ?

  • G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
  • G06Q 50/22 - Social work

100.

Use of TNFα inhibitor for treatment of psoriatic arthritis

      
Application Number 14681713
Grant Number 09085620
Status In Force
Filing Date 2015-04-08
First Publication Date 2015-07-21
Grant Date 2015-07-21
Owner AbbVie Biotechnology Ltd. (Bermuda)
Inventor
  • Hoffman, Rebecca S.
  • Weinberg, Mark
  • Banerjee, Subhashis
  • Taylor, Lori K.
  • Spiegler, Clive E.
  • Tracey, Daniel E.
  • Chartash, Elliot K.
  • Barchuk, William T.
  • Yan, Philip
  • Murtaza, Anwar
  • Salfeld, Jochen G.
  • Fischkoff, Steven A.
  • Granneman, George R.

Abstract

The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  1     2     3        Next Page